Bastiano Sanna - Feb 14, 2023 Form 4 Insider Report for VERTEX PHARMACEUTICALS INC / MA (VRTX)

Role
EVP, Cell & Genetic Therapies
Signature
/s/ Christiana Stevenson, Attorney-in-Fact
Stock symbol
VRTX
Transactions as of
Feb 14, 2023
Transactions value $
-$655,161
Form type
4
Date filed
2/16/2023, 03:16 PM
Previous filing
Feb 14, 2023
Next filing
Feb 22, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction VRTX Common Stock Sale -$571K -1.9K -3.07% $300.29 60K Feb 14, 2023 Direct F1, F2, F3
transaction VRTX Common Stock Sale -$84K -279 -0.46% $301.11 59.7K Feb 14, 2023 Direct F1, F2, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Transaction made pursuant to Mr. Sanna's company approved trading plan under Rule 10b5-1.
F2 Mr. Sanna undertakes to provide (upon request by the SEC staff, the issuer or a security holder of the issuer) full information regarding the number of shares sold at each separate price.
F3 Open market sales reported on this line occurred at a weighted average price of $300.29 (range $300.00 to $300.92).
F4 Open market sales reported on this line occurred at a weighted average price of $301.11 (range $301.02 to $301.22).